Cell Microarrays versus other methods

Our technology delivers:

  • Highest success rate for identification of specific cell surface targets/receptors
  • Low false positive rates

The main alternatives for identifying receptor interactions have low success rates as they do not provide a natural, human environment for interactions to occur with fully folded proteins. They are also often time consuming and require expensive in-house expertise and equipment.

Due to our high success rates, a major pharmaceutical client has estimated that our service only requires around 10% of the investment that would be needed for them to achieve the same results in-house.  Our clients are able to focus on other areas whilst our expert team of scientists work on delivering results in around eight weeks.

 

Retrogenix’s high rates of success in target deconvolution, receptor identification and off-target screening are due to:

High Success Rates
Physiological
Relevance
Expression in human cells results in correct folding and plasma membrane localisation and allows for multimerisation and the detection of interactions mediated by post-translational modifications such as glycosylation.
Broad
Coverage
At >4,500 full-length clones, our microarrays represent around 70% of all known plasma membrane proteins providing the highest likelihood of identifying a ligand’s specific target.
Full-length
Proteins
Full-length, non-fused human proteins are expressed in human cells – a real advantage over traditional protein arrays.
Rapid
Turnaround
Results typically delivered in 6-8 weeks.
Expertise &
Collaborate
Focus
Studies are co-designed with clients in order match their needs. Dialogue is maintained throughout and a comprehensive report with data interpretation delivered on completion.
Sensitivity
Specificity
Ligand-receptor interactions around 10 micromolar can be detected even without any amplification strategies. Reproducibility is key, resulting in the detection of specific, biologically-relevant targets.
Direct
Binding
As the Retrogenix technology detects direct binding of drug to proteins, and is not a competition-based assay, we can discover important allosteric interactions.
Versatility
Compatible with a range of detection methods including anti-His, anti-Flag, anti-V5, anti-Fc, biotin-streptavidin, directly fluorescently tagged and radiolabeled molecules.

The Retrogenix Cell Microarray Technology outperforms standard methods on a range of key features:

 

Retrogenix Standard Protein Array Pull Down + Mass Spec
Likelihood of identifying specific cell surface target
Likelihood of identifying specific off-targets
Level of specificity (low hit number)
Speed
Through put
Low cost
Library size
Lack of false positives
Lack of false negatives ✓✓✓
Post-translational modifications and folding ✓✓✓
Multi subunit targets
Species of target HUMAN MAINLY HUMAN ANY
Expression system HUMAN INSECT OR YEAST NATIVE

*but are subject to denaturation

Case Studies

Retrogenix’s results are now supporting patent applications, appearing in peer-reviewed publications and being presented at international conferences.

Find out about how the Retrogenix Technology has been used:

Case Studies

 

FAQ: “What data will I receive?”

A full report presenting and interpreting the results of the screens is provided at the end of the study. On request, members of the Retrogenix team can also present and discuss the results via a web meeting.

More FAQs

Talk to us about a project
Please leave this field empty.
Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
We’ve developed a terrific working relationship with the team at Retrogenix and intend to utilize their microarray technology as a standard screen for future targets. Jim and Jo have become trusted collaborators and we appreciate their flexibility and willingness to work with us through some challenging issues. The quality and timeliness of the data and reports are first rate. We’ve come to rely on their results as a dependable means to confirm results from traditional crossreactivity studies and to identify additional potential unexpected interactions.
Amy Bourdeau, ‎Senior Preclinical Development Coordinator, Bluebird bio